Hide Board Information

Show Board Information

NORDEA BANK FINLAND 2.25% CVD BDS 16/11/15 EUR50000 95BT

Board Mod: Add me as mod

Asst Mods:

Last Post: 06/04/2012 2:03:26 AM

Board Marks: 0

Posts Today: 0

Board Views Today: 1

NORDEA BANK FINLAND 2.25% CVD BDS 16/11/15 EUR50000 (95BT) Stock Message Board

Find 95BT Recent News, 95BT Filings, 95BT Stock Quote, 95BT Stock Chart, 95BT Research & Opinions Below

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

Be the first to post on NORDEA BANK FINLAND 2.25% CVD BDS 16/11/15 EUR50000 95BT

Recent Articles

• Investors of Kyverna Therapeutics Can Pursue Class Action
• Xi Jinping Supports Hong Kong's Economic Strategies and Development
• Solar Alliance Energy Gains Shareholder Approval in Key Meeting
• Fruit Street Health Enhances Diabetes Prevention with Meals
• CNOOC Limited Partners with INEOS Energy in New Agreement
• Exciting Collaboration: Celebrate Japan's Fruit Culture
• Investors Urged to Act Before Deadline in Xiao-I Class Action
• Karma Sauce Applauds First We Feast's Bold New Direction
• Cassava Sciences Investors Encouraged to Act on Stock Losses
• Investors Warned of Upcoming Deadline in WM Technology Case
• Investors Urged to Act: Acadia Healthcare Class Action Deadline
• Aehr Test Systems Faces Class Action, Investors Urged to Act Soon
• Investors Alert: Upcoming Lead Plaintiff Motion Deadline for CUBI
• Legal Action Announced for Five9, Inc. Investors Following Stock Decline
• Legal Action Launched for Kyverna Therapeutics Investors
• Everlight Solar's Culture: A Testament to Team Camaraderie and Growth
• Haloid Enhances Safety in Film Productions with Reviews
• Insights on the Growing Demand for Edible Coatings in Produce
• Prospect Ridge Resources Adjusts Plans for Upcoming Meeting
• Legal Update: Toronto-Dominion Bank Securities Class Action
• Key Updates from Nasdaq on the Nasdaq-100 Index Changes
• TeraBox Revolutionizes File Sharing with Free Unlimited Service
• Kessler Topaz Takes Action Against Enphase Energy for Fraud
• Demesne Resources Completes Second Tranche of Financing
• Spiro Celebrated as One of the Top Agencies in Marketing
• Global Uranium Corp. Launches Strategic Marketing Efforts
• UnitedHealth Group Clarifies Misconceptions and Updates Claims
• Neurocrine Biosciences Unveils Potential of CRENESSITY™ for CAH
• Acadia Healthcare Investors Urged to Take Action on Lawsuit
• Global Uranium Corp. Unveils C$1.5 Million Flow-Through Offering
• Rakovina Therapeutics Secures $3M to Propel Cancer Therapy Advances
• Hola Prime's Innovative Vision: New Marketing Director Appointed
• Teamsters Advocate for Stronger Standards on Autonomous Vehicles
• BioVaxys Secures Funding and Enters Debt Settlement Agreement
• Exciting Advancement as UNLOXCYT Gains FDA Approval for Treatment
• OFS Credit Company Shares November Net Asset Value Insights
• New FDA Approval for Crenessity Enhances CAH Treatment Options
• Q-Gold Secures Initial Funding for New Exploration Ventures
• Capital Power's Genesee Project Marks Major Energy Milestone
• Viridian Therapeutics Set to Present Veligrotug Results Soon
• Ensuring Safe Travels: King County's Holiday Traffic Initiative
• Acadia Healthcare Faces Class Action Amid Significant Losses
• S&P Dow Jones Indices Reveals Results of 2024 DJSI Review
• Celebrating Entrepreneurial Success: The Impact of MBDA
• Village Super Market's Dividend Announcement and Growth Plans
• Digi International Welcomes New Executive Leaders to Board
• Transfusion Market Expected to Rise by $2.6 Billion: Insights
• CenterPoint Energy Announces Increased Quarterly Dividend Payout
• Shobha Launches Exciting Offers and Convenient Memberships
• ANSC Secures Key Approval for Upcoming Business Combination